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Abstract
 
Bacterial pneumonia is an increasing complication of HIV infection and inversely correlates with
the CD4
 
 
 
 lymphocyte count. Interleukin (IL)-17 is a cytokine produced principally by CD4
 
 
 
 T
cells, which induces granulopoiesis via granulocyte colony-stimulating factor (G-CSF) produc-
tion and induces CXC chemokines. We hypothesized that IL-17 receptor (IL-17R) signaling is
critical for G-CSF and CXC chemokine production and lung host defenses. To test this, we
used a model of 
 
Klebsiella pneumoniae
 
 lung infection in mice genetically deficient in IL-17R or in
mice overexpressing a soluble IL-17R. IL-17R–deficient mice were exquisitely sensitive to in-
tranasal 
 
K. pneumoniae
 
 with 100% mortality after 48 h compared with only 40% mortality in
controls. IL-17R knockout (KO) mice displayed a significant delay in neutrophil recruitment
into the alveolar space, and had greater dissemination of 
 
K. pneumoniae
 
 compared with control
mice. This defect was associated with a significant reduction in steady-state levels of G-CSF and
macrophage inflammatory protein (MIP)-2 mRNA and protein in the lung in response to the
 
K. pneumoniae
 
 challenge in IL-17R KO mice. Thus, IL-17R signaling is critical for optimal pro-
duction of G-CSF and MIP-2 and local control of pulmonary 
 
K. pneumoniae
 
 infection. These
data support impaired IL-17R signaling as a potential mechanism by which deficiency of CD4
lymphocytes predisposes to bacterial pneumonia.
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Klebsiella 
pneumoniae
 
 • chemokine
 
Introduction
 
The development of bacterial pneumonia depends on a
complex interplay between virulence factors of the organ-
ism and lung host defenses. Host resistance requires both
innate and adaptive immune responses, which are largely
initiated by growth factors termed cytokines. Bacterial
pneumonias are an increasingly recognized complication of
HIV infection and the incidence of these infections in-
versely correlates with the CD4
 
 
 
 lymphocyte count (1, 2).
Some investigators have hypothesized that the increased
susceptibility to bacterial pneumonia is due to lack of T cell
help and generation of opsonic antibody by B cells (3). Re-
cently a novel cytokine, IL-17, has been found to be pro-
duced largely by activated CD4
 
 
 
 lymphocytes (4, 5). IL-17
has been shown to stimulate granulopoiesis both in vitro
(6) and in vivo (7). Our laboratory has demonstrated that
induction of in vivo granulopoiesis by IL-17 is partly due
to stimulation of G-CSF and the transmembrane form of
stem cell factor (8). Moreover, IL-17 has been shown to
induce the production of TNF-
 
 
 
 (9) and CXC chemo-
kines (10) in the lung, and our lab has demonstrated its re-
lease into the lung in experimental 
 
Klebsiella pneumoniae
 
 in-
fection (11). In contrast to the relative restriction of IL-17,
the IL-17R is ubiquitously expressed in a variety of tissues
(12). Based on these data we hypothesized that IL-17R sig-
naling is critical for lung CXC chemokine generation, in-
duction of G-CSF, a cytokine required for ongoing neu-
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trophil production in response to infection, and lung host
defense (13). We tested this hypothesis in mice deficient in
IL-17R signaling using IL-17R knockout (KO)
 
*
 
 mice or
mice overexpressing a soluble IL-17R:Fc fusion protein to
exclude a development defect associated with the IL-17R
KO mice. Using a well-described model of 
 
K. pneumoniae
 
infection we found that IL-17R signaling is critical for
early neutrophil recruitment and local induction of G-CSF
and macrophage inflammatory protein (MIP)-2 at both the
mRNA and protein level. Moreover, IL-17R–deficient
mice had a significantly greater incidence of bacteremia and
mortality in response to 
 
K. pneumoniae
 
 infection.
 
Materials and Methods
 
Generation of IL-17R–deficient Mice by Homologous Recombina-
tion.
 
Genomic clones encoding murine IL-17R were isolated
from a 129 derived lambda library using a murine IL-17R cDNA
probe (4) and mapped by a combination of PCR, restriction di-
gest, and sequence analyses using deposited genomic sequences
corresponding to IL-17R locus on mouse chromosome 6 (Gen-
Bank/EMBL/DDBJ accession no. AC018559). A gene targeting
vector was constructed by replacing 5.7 kb of genomic sequence
containing exons 4–11 (corresponding to nucleotides 445–1,172
of the murine IL-17R cDNA) with a PGKneo cassette. A thymi-
dine kinase cassette (MC-TK) was inserted into the 5
 
 
 
 end of the
vector. 129 derived embryonic stem (ES) cells were electropo-
rated with the targeting vector and selected in the presence of
G418 and ganciclovir as described (14). ES clones carrying a tar-
geted mutation in IL-17R were identified by a combination of
PCR and genomic Southern blot analyses and were injected into
C57BL/6 blastocysts. The resulting male chimeras were crossed
to C57BL/6 females to generate mice heterozygous for the IL-
17R mutation (IL-17R
 
 
 
/
 
 
 
), which were subsequently inter-
crossed to generate IL-17R–deficient mice (IL-17R KO). These
mice were moved to a C57BL/6 background by five successive
backcrosses to C57BL/6 mice.
 
Animals.
 
Specific pathogen-free C57BL/6 mice (6–8-wk-old,
male, average weight 25 g; National Cancer Institute, Frederick,
MD) were used in all experiments as the control mice. IL-17R
KO mice were obtained from Immunex Corporation and bred in
LSUHSC Animal Care Facilities. The IL-17R KO mice were
confirmed genetically by PCR. Male 6–8-wk-old IL-17R KO
and C57BL/6 mice were used in this study. IL-17R
 
 
 
/
 
 
 
 mice
were generated by crossing IL-17R KO mice with C57BL/6
mice. All mice were housed in specific pathogen-free room
within the Animal Care Facility of Louisiana State University
Medical Center Vivarium under an IACUC-approved protocol,
provided with water ad libitum and food, and housed under 12–h
light/dark cycles until date of experiment.
 
IL-17 Binding and Flow Cytometry.
 
Surface IL-17R expres-
sion was detected by flow cytometry using murine IL-17.Fc on
gated populations of either splenocytes, or peritoneal exudate
cells obtained 18 h after intraperitoneal injection of 3 ml 3%
thioglycollate broth (Sigma-Aldrich). Briefly, after incubation in
50 
 
 
 
l blocking buffer containing 2% normal mouse serum, 2%
 
normal goat serum, and 10 
 
 
 
g Fc Block (BD PharMingen), 10
 
6
 
cells were incubated with either 20 
 
 
 
g/ml murine IL-17.Fc or
the negative control, human IL-4R.Fc, and then stained with bi-
otinylated mouse anti–human IgG1 Fc (Jackson ImmunoRe-
search Laboratories) and streptavidin-allophycocyanin (APC; BD
PharMingen). PE- and FITC-conjugated antibodies against CD4,
CD8, Gr-1, and CD19 were purchased from BD PharMingen.
 
K. pneumoniae Infection. K. pneumoniae
 
 strain 43816, serotype 2
(American Type Culture Collection) was grown in tryptic soy
broth (Difco) for 18 h at 37
 
 
 
C. 1 ml of the culture was added into
200 ml of fresh tryptic soy broth, and grown for another 2 h until
the organism reached log phage. Bacteria was pelleted by centrifu-
gation at 5,000 rpm for 15 min, washed twice in PBS, and resus-
pended at desired concentration. The concentration of 
 
K. pneumo-
niae
 
 was determined by measuring the absorbency at 600 nm. A
standard of absorbencies based on known CFUs was used to cal-
culate inoculum concentration. For inoculation, mice were briefly
anesthetized with ether. The bacterial inoculum (50 
 
 
 
l) was ap-
plied to the nose tip of mouse with a pipet tip and involuntarily
inhaled. Mice were held vertically for 2 min after the inoculation.
 
Bronchoalveolar Lavage.
 
At serial time points, mice were anes-
thetized with Ketamine (Schering-Plough Animal Health Corp).
A tracheal cannula was inserted into the upper cervical trachea
through a tracheotomy. The lungs were lavaged with 0.5-ml ali-
quots of warmed PBS 
 
 
 
 0.5 mM EDTA up to 11 ml. The first
ml of recovered bronchoalveolar lavage (BAL) fluid was centri-
fuged at 500 
 
g 
 
and the supernatant was stored at –80
 
 
 
C for subse-
quent cytokine ELISAs. The remaining cell pellet was combined
with the other lavage fluid and analyzed for total cell count fol-
lowed by differential cell counts performed in cytospins stained
with Wright-Giemsa (Baxter McGaw Park).
 
Lung Histological Examination.
 
At serial time points, mice were
anesthetized followed by euthanasia by transection of the abdomi-
nal aorta. The lungs were removed en bloc and inflated with 10%
formalin up to 20 cm H
 
2
 
O. The lungs were placed in 10% forma-
lin and subsequently embedded in paraffin. Sections were stained
with hematoxylin and eosin for histological examination.
 
K. pneumoniae CFU in Lung Homogenates.
 
At serial time points
after 
 
K. pneumoniae
 
 challenge, mice were killed and the lungs
were then removed aseptically. The lung was placed in sterile
PBS (volume ml 
 
  
 
0.9 
 
 
 
 the lung tissue weight g) and homoge-
nized with a tissue homogenizer. The lung homogenates were
placed on ice, and serial 1:10 dilutions were made. 10 
 
 
 
l of each
dilution were plated on soy base blood agar plates (Difco) and in-
cubated for 18 h at 37
 
 
 
C, then colonies were counted. Bacterial
concentrations were expressed in terms of CFU/lung.
 
Total RNA Isolation and Ribonuclease Protection Assays.
 
At serial
time points after 
 
K. pneumoniae
 
 infection, mice were euthanized
and the lungs were perfused blood free by injection of PBS
through the right ventricle. Lungs were homogenized in Trizol
solution (Life Technologies). 20 
 
 
 
g of total RNA from each
sample was used for ribonuclease protection assay (RPA) with
mCK-4 and mCK-5 templates, purchased from BD PharMingen,
following the manufacturer’s protocol.
 
ELISA for MIP-2, G-CSF, and IL-17.
 
MIP-2 and IL-17 was
measured by ELISA kits (R&D Systems) following the manufac-
turer’s protocol. G-CSF was measured using a sandwich ELISA
using matched antibody pairs from R&D Systems.
 
Statistical Analysis.
 
Comparison between means was performed
with analysis of variance (ANOVA) followed by Fisher’s follow-
up testing. Survival comparisons were performed using Kaplan-
Meier analysis (StatView; Abacus Concepts). 
 
P 
 
  
 
0.05 was con-
sidered to represent a significant difference.
 
*
 
Abbreviations used in this paper:
 
 ANC, absolute neutrophil count; BAL,
bronchoalveolar lavage; ES, embryonic stem; KO, knockout; MIP, mac-
rophage inflammatory protein; RPA, ribonuclease protection assay; SCF,
stem cell factor. 
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Results
 
Generation of IL-17R KO Mice.
 
Mice genetically defi-
cient in IL-17R (IL-17R KO) were generated by homol-
ogous recombination in ES cells using a targeting vector
that replaces exons 4–11, encoding nucleotides 445–1,172
of the IL-17R cDNA (4), with a PGK-neo cassette (Fig. 1
A). Southern blot analyses of genomic DNAs derived from
wild-type, IL-17R
 
 
 
/
 
 
 
, and IL-17R KO genomic con-
firmed that the IL-17R gene was disrupted by specific
gene targeting (Fig. 1 B). IL-17R KO mice were born at
the expected Mendelian frequency from IL-17R
 
 
 
/
 
 
 
 inter-
crosses (data not shown) and displayed no gross external
phenotype. To confirm that the targeted mutation abro-
gates IL-17 binding, flow cytometric analyses using IL-17:
Fc (4) were performed on subpopulations of wild-type and
IL-17R KO spleen and peritoneal exudate cells. As shown
in Fig. 1 C, IL-17R KO T cells, B cells, and myeloid cells
fail to bind IL-17, whereas binding is clearly observed to
wild-type cells.
 
IL-17R Signaling Is Required for Survival Against K. pneu-
moniae Infection.
 
Pilot studies were performed with vary-
ing does (3 
 
 
 
 10
 
3
 
–10
 
6
 
 CFU) of 
 
K. pneumoniae
 
 given intra-
nasally to 6–8-wk-old male C57BL/6 mice (
 
n
 
 
 
  
 
56). Based
on these experiments, the LD50 (at 12 d) of 
 
K. pneumoniae
 
was determined to be 3 
 
 
 
 10
 
4
 
 CFU. We have previously
shown that this inoculum can induce IL-17 within 12 h of
infection in the lungs of mice (11). Based on these studies
we chose 3 
 
 
 
 10
 
3
 
 and 10
 
4
 
 CFU for subsequent intranasal
challenges in control and IL-17R–deficient mice. IL-17R
KO mice showed a significantly reduced survival rate after
 
K. pneumoniae
 
 inoculation. At the 10
 
4
 
 CFU dose, 100% of
IL-17R KO mice perished by 48 h, compared with only
20% of the controls (Fig. 2 A). At 3 
 
 
 
 10
 
3
 
 CFU dose, 80%
of IL-17R KO mice were dead by day 7, compared with
only 40% of the controls (Fig. 2 A). Although IL-17R KO
mice have normal peripheral blood counts and normal
numbers of CD4
 
 
 
 and CD8
 
 
 
 lymphocytes in the blood
and spleen (12), we needed to exclude any potential devel-
opmental defects in these mice, which could, in part, ex-
plain a reduced survival to 
 
K. pneumoniae
 
 challenge. To ac-
complish this, we constructed a fusion protein consisting of
the IL-17R extracellular domain with the murine IgG
 
1
 
CH2 and CH3 domains using recombinant PCR as de-
scribed previously by our group with the TNF p55 extra-
cellular domain (15). The IL-17R:Fc fusion protein mi-
grated as a 140-kD dimer on nonreduced SDS-PAGE (Fig.
2 B). Moreover, this protein is biologically active, as it sig-
nificantly inhibited recombinant IL-17–induced produc-
tion of IL-6 by 3T3 fibroblasts (data not shown). To ex-
press this construct in vivo we generated an E1-deleted
recombinant adenovirus (AdIL17R/Fc) as described previ-
ously (15). C57BL/6 mice were administered 10
 
9
 
 PFU of
AdIL17R/Fc or AdLuc (which encodes firefly luciferase) as
a control. 72 h later (the time of maximal expression of the
IL-17R:Fc fusion protein), mice were given an intranasal
challenge with 3 
 
 
 
 10
 
3
 
 CFU 
 
K. pneumoniae
 
. Parallel studies
were performed in IL-17R KO mice or littermate controls.
Both AdIL-17R/Fc–treated mice and IL-17R KO mice
had a similar phenotype in that their survival was signifi-
cantly worse than control mice (Fig. 2 C).
 
Lung Bacterial Burden after K. pneumoniae Intranasal Chal-
lenge.
 
The bacterial burden of 
 
K. pneumoniae
 
 was deter-
mined by quantitative culture of lung homogenates. Intra-
Figure 1. Generation of IL-17R KO mice. (A) A gene
targeting vector was constructed that replaces exons 4–11
with a PGK-neo cassette. A thymidine kinase cassette
(MC-TK) was inserted into the 5  end of the vector in the
opposite orientation of the IL-17R gene. Exons are de-
picted as filled boxes. The initiation (ATG) and termina-
tion (TAG) codons as well as the transmembrane domain
(TM) are indicated. The Asp718 restriction sites and probe
used for genomic Southern blot analyses are indicated. (B)
Genomic DNAs from wild-type ( / ), IL-17R / , and
IL-17R KO mice were digested with Asp718 and subject
to Southern blot analysis using the depicted probe. The
sizes of the mutant and wild-type alleles are indicated. (C)
Analysis of IL-17 binding to wild-type and IL-17R–defi-
cient cells. The binding of IL-17:Fc to wild-type ( / )
and IL-17R–deficient ( / ) spleen cells gated on expres-
sion of the T cell markers CD4 or CD8 or the B cell
marker CD19 as well as thioglycollate elicited peritoneal
exudate cells gated on expression of the granulocytic
marker Gr-1 was determined by flow cytometry and
shown in the shaded histograms. Background binding to
an irrelevant Fc protein is shown in the open histograms. 
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pulmonary growth of 
 
K. pneumoniae
 
 was similar in control
and IL-17R KO mice for the first 18 h of infection (Fig. 3).
However, by 24 h there were significantly greater organ-
isms in the lungs of IL-17R KO mice compared with con-
trol mice. This accentuated growth was observed up to 48 h.
Thereafter, there was significant mortality in the IL-17R
KO mice and thus comparisons of bacterial burdens at late
time points between the IL-17R KO mice and control
mice were not made due to selection bias for surviving
mice. However, surviving control mice showed a decline
in lung burden by 56 h (data not shown). Moreover, IL-
17R KO mice all had positive spleen culture at 18 h after
 
K. pneumoniae challenge (n   10) compared with only 2 of
10 control mice.
Failure of IL-17R KO Mice to Mobilize and Recruit Neutro-
phils to the Lung. Absolute neutrophil counts (ANCs) were
measured in blood and BAL fluid over time in control and
IL-17R KO mice after K. pneumoniae challenge. Baseline
blood ANC was similar in both groups of mice (Fig. 4 A).
After K. pneumoniae challenge, control mice demonstrated
a mild increase in blood ANCs up to 6 h, which was not
observed in IL-17R KO mice (Fig. 4 A). Both groups of
mice showed a transient fall in blood ANCs at 6 h. This
was followed by a significant increase in blood ANCs in
control mice, which peaked at 18 h, and slowly declined as
the infection was controlled (Fig. 4 A). In contrast, IL-17R
KO mice showed a significant attenuation in blood ANCs
at 18, 24, and 48 h and these mice were significantly neu-
tropenic by 48 h, consistent with overwhelming infection.
Control mice demonstrated the ability to recruit significant
numbers of neutrophils into the lung, as measured by the
ANCs in the BAL fluid (Fig. 4 B). In contrast, IL-17R KO
mice displayed decreased neutrophil recruitment, which
was statistically lower than control mice up to 18 h into the
infection (Fig. 4 B). This decreased neutrophil recruitment
was also supported by a reduced level of lung myeloperox-
idase activity measured at 12 h into the infection (Fig. 4 C).
Lungs from both control and IL-17R KO mice were
morphologically normal before K. pneumoniae challenge
(Fig. 5). 18 h after 104 CFU, both groups of animals
showed focal peribronchiolar inflammation (Fig. 5). How-
ever, by 24 h, IL-17R KO mice developed significant areas
of perivascular edema and associated with large number of
organisms in the perivenous space (Fig. 5). The combina-
tion of delayed neutrophil recruitment and the early dis-
semination of bacteria as measured by splenic culture and
Figure 2. Reduced survival of mice deficient in IL-17R
signaling. (A) IL-17R KO, IL-17R / , or control mice
(n   10 each group) were challenged with intranasal K.
pneumoniae and survival was recorded every 12 h. To con-
firm that the reduced survival phenotype was due to a lack
of IL-17R signaling and not due to a developmental de-
fect, 6–8-wk-old IL-17R KO mice or C57BL/6 mice in-
fused with AdIL-17R Fc (Western blot of IL-17R/Fc fu-
sion protein depicted in B) or a control virus were
challenged with intranasal K. pneumoniae and survival was
recorded every 12 h (C; n   10 each group).
Figure 3. K. pneumoniae growth curves in control and IL-17R KO
mice (n   4–6, *P   0.05).523 Ye et al.
histologically by perivascular organisms led us to investigate
known factors involved in early host defense against K.
pneumoniae, specifically the CXC chemokine, MIP-2 (16).
Moreover, a failure to increase peripheral blood ANCs
suggested that IL-17R signaling was required for infection-
induced granulopoiesis, which is partly dependent on
G-CSF and stem cell factor (SCF; reference 8). This led us
to investigate whether IL-17R signaling was involved in
lung MIP-2, G-CSF, and SCF production.
Failure of IL-17R KO Mice to Induce expression of MIP-2,
G-CSF, and SCF. For these experiments both IL-17R
KO and control mice were challenged intranasally with 104
CFU of K. pneumoniae. 12 h later when bacterial burdens
were similar, but myeloperoxidase (MPO) and neutrophil
recruitment were significantly different between both
groups of animals, mice were killed and total RNA was iso-
lated from whole lung. Transcripts for G-CSF, SCF, and
MIP-2 were measured by RPA. Transcripts were normal-
ized to the L32 transcript. The results indicated that after the
K. pneumoniae challenge, IL-17R KO mice failed to signifi-
cantly induce either G-CSF or SCF (Fig. 6). No G-CSF or
SCF transcripts were detected in unchallenged IL-17 R KO
or control mice (data not shown). Moreover, IL-17R KO
mice also demonstrated significantly lower transcripts for
MIP-1 , MIP-1 , and MIP-2 (Fig. 6). Attenuation of lung
MIP-2 in IL-17R KO mice was also confirmed at the pro-
tein level at both 12 and 24 h after K. pneumoniae infection.
No G-CSF protein was detected in the BAL fluid 12 h after
K. pneumoniae infection. However, G-CSF was readily de-
tectable at 24 h in BAL fluid of control mice but was re-
duced by over 60% in IL-17R KO mice (Fig. 7). IL-17 was
also readily detectable in BAL fluid at 12 and 18 h after K.
pneumoniae infection in both control and IL-17R KO mice
(Fig. 7) and thus, local release of IL-17 is part of the normal
host response to this infection.
Our laboratory has previously shown that G-CSF is not
compartmentalized in the lung such as other growth factors
such as TNF (17, 18). Thus, the lung may be a significant
source of G-CSF during infection, which results in an
appropriate granulopoietic response (17). To investigate
whether granulopoiesis was altered in response to infection,
splenic CFU-GM and high proliferative potential (HPP)
colonies were measured at 0 and 18 h after K. pneumoniae
infection, as described previously (7). Control mice dem-
onstrated a 98   16% increase in CFU-GM and a 189  
31% increase in HPP, whereas IL-17R KO mice showed a
7   5% and a 15   8% decrease (P   0.01, ANOVA).
These data are consistent with the fact that IL-17R KO
could not appropriately increase their ANCs in response to
K. pneumoniae infection (Fig. 4).
Discussion
IL-17, a 32-kD dimer, is a cytokine produced principally
by activated CD4  T cells. It signals through a unique type
I transmembrane receptor, which is ubiquitously distrib-
uted. Interestingly, the cytoplasmic domain has no known
homology with existing known signaling pathways (12).
IL-17 clearly supports hematopoiesis both in vitro and in
vivo (6, 7). IL-17–induced hematopoiesis results in matura-
tion of cells along the granulocytic pathway (6, 7). More-
over, IL-17 has been shown to induce translocation of nu-
clear factor (NF)- B and production of IL-1 and TNF by
monocyte/macrophages (9). The proinflammatory nature
of this cytokine has also been implicated in inflammatory
arthritis (9, 19, 20), lung inflammation (10, 21), organ al-
lograft rejection (22), and infection with K. pneumoniae
(11). To further define the role of this ligand/receptor in
Figure 4. Reduced ANCs in the blood and lungs of IL-17R KO mice
in response to K. pneumoniae infection. (A) Attenuation of increase in
blood ANC in IL-17 R KO mice (n   5–8, * denotes P   0.05). (B) Re-
duction in lung neutrophil recruitment as measured as ANCs in BAL
fluid (BALF) in IL-17R KO mice (n   5–8, * denotes P   0.05). (C)
The reduced lung neutrophil recruitment was associated with a significant
decrease in lung MPO activity in IL-17 R KO mice (n   5–8, * denotes
P   0.05).524 IL-17R Signaling and Lung Host Defense525 Ye et al.
regulating inflammatory response, we analyzed the re-
sponse of mice deficient in IL-17 signaling to K. pneumo-
niae infection. We chose this model because host defense is
dependent on CXC chemokine expression (16) and data
from our laboratory and others has demonstrated that IL-17
is a potent inducer of lung chemokine expression (10).
Moreover, microbial lipopeptides have been shown to be
potent inducers of IL-17 in T cells (23).
Our data demonstrate that IL-17R signaling is critical for
lung chemokine gene expression, early lung neutrophil re-
cruitment, and survival against K. pneumoniae challenge.
Moreover, IL-17 was readily detectable in BAL fluid as
early as 12 h after K. pneumoniae infection and thus is a nor-
mal response to infection with this pathogen. In fact, IL-
17R KO mice had higher levels of IL-17, suggesting that
this receptor is important in clearance of IL-17 from the
lung. Although we did not directly investigate the source
of IL-17 in the lung in these studies, studies ongoing in our
laboratory support the fact that both CD4  and CD8  T
cells are detectable in the lung as early as 6 h after K. pneu-
Figure 5. Representative lung histology of control and IL-17R KO mice after K. pneumoniae challenge. At 0 h, the lungs of control wild-type mice
and IL-17R KO mice were essentially normal with no inflammatory infiltrate and mild edema. 18 h after infection there is minimal perivascular infiltra-
tion of neutrophils and moderate edema in the lungs of wild-type mice at 18 h after infection. In contrast, IL-17R KO mice had perivascular, peribron-
chiolar, and intraalveolar neutrophils at 18 h after infection associated with moderate diffuse perivascular edema. At 24 h after infection, wild-type mice
had minimal perivascular infiltration of neutrophils and moderate edema in the lungs. In contrast, IL17R /  mice had severe perivascular edema that par-
tially compressed and distorted adjacent alveoli. Within, and marginating the edema were large numbers of degenerate neutrophils and large numbers of
bacterial rods compared with few visible bacteria in control mice (all images 40 ).
Figure 6. Analysis of lung gene
expression by RPA. (A) Repre-
sentative gel of lung G-CSF and
SCF gene expression after K.
pneumoniae challenge. (B) Densi-
tometric analysis of G-CSF and
SCF gene expression (n   3–4,
*P    0.05). (C) Representative
gel of lung chemokine gene ex-
pression after K. pneumoniae chal-
lenge. (D) Densitometric analysis
of MIP-2 gene expression (n  
3–4, * P   0.05). bact., bacteria.
Figure 7. BAL fluid levels of G-CSF, MIP-2, and IL-17 after K. pneu-
moniae challenge.526 IL-17R Signaling and Lung Host Defense
moniae infection, and represent a significant source of IL-17
in this infection model, as described previously (4, 5).
These data further suggest that lung lymphocytes can influ-
ence antibacterial host defenses within the first 12–24 h of
infection, which is largely an innate response. In further
support of this concept, our laboratory has previously
shown that depletion of CD4  T cells can attenuate lung
macrophage production of TNF after intratracheal endo-
toxin administration (24).
In summary, our study shows that the lack of signaling
via IL-17Rs severely impairs host defense against K. pneu-
moniae infection in a mouse model. We found that the
ANC both in blood and lungs in IL-17R KO mice was sig-
nificantly lower compared with control mice after infec-
tion. Moreover, this failure to increase the ANCs in blood
was associated with failure to increase neutrophil progeni-
tors in splenic CFU assays. IL-17R KO mice failed to nor-
mally induce MIP-2, a chemokine gene critical for neutro-
phils diapedesis and chemotaxis into the lung (16), and
G-CSF, a growth factor that is produced in the lung in re-
sponse to infection, which secondarily increases granu-
lopoiesis (13). The excessive growth of bacteria in the lungs
of IL-17R KO mice was associated with significantly more
perivascular edema and bacterial dissemination compared
with control mice. These data demonstrate that signaling
through the IL-17R is critical for lung PMN recruitment
and host defenses against K. pneumoniae. We speculate that
relative IL-17 deficiency may in part explain the pulmonary
host defense defect associated with either HIV infection or
congenital immunodeficiency of CD4  lymphocytes.
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